$2.2 billion

Dallas’ Peloton Therapeutics Exits to Merck in $2.2B Deal

by | May 22, 2019
The clinical-stage oncology company develops small molecule drugs to treat kidney cancer and other diseases. Its renal cell carcinoma drug is in a Phase II clinical trial.
MORE